<DOC>
	<DOCNO>NCT00294489</DOCNO>
	<brief_summary>A relatively large proportion patient chronic HCV infection normal mildly elevate ALT . Many patient treat , send liver biopsy . The present study determine ability Methcetin BreathID Test ( MBIT ) detect patient candidate anti-viral treatment , alternative measure liver biopsy decision-making prior treatment clinical hepatology .</brief_summary>
	<brief_title>Methacetin Breath Test HCV Patients With Normal Near-Normal ALT</brief_title>
	<detailed_description>The rational use MBIT management HCV patient persistently normal ( slightly elevate ) ALT : - If MBIT impair , indicate fibrosis &gt; 2 : trigger begin treatment - This strategy enable treat patient relatively severe disease detect biopsy . - HMOs recognize cost-effectiveness anti-viral therapy patient , mean prevention deterioration , cirrhosis HCC . - If MBIT indicate low fibrosis = &gt; treatment may defer , follow-up perform detect possible degradation indicate need treatment . - Today AASLD guideline allow treatment HCV RNA+ patient normal ALT . In view limited effectivity therapy , cost side effect , likely many individual therapy safely defer , lead cost saving . - MBIT may replace need liver biopsy decision- making HCV . - Even patient genotype 1 elevated ALT , risk side effect , treatment may delay low fibrosis ( e.g . &lt; 2 ) . GOAL : • To assess ability MBIT improve management patient liver disorder AIM : • To determine whether Methacetin BreathID Test ( MBIT ) useful evaluation HCV RNA positive patient normal minimally elevate ALT determine severity liver disease guide decision-making routine clinical use . OBJECTIVE : AUC &gt; 0.75 ( +/-10 % 95 % CI ) detection fibrosis &gt; 2 . INCLUSION CRITERIA : - Men woman &gt; 18 - Patients HCV RNA+ 105 copy Patients normal liver enzymes two test 3 month apart , &lt; X1.5 upper normal - Patients biopsy proven HCV ( 9 month prior test anticipate change liver disease since biopsy ) . EXCLUSION CRITERIA : - Other liver disorder . - Active infection . - Use drug know induce/suppress P4501A2 - Pulmonary disease - Consumption &gt; 20cc alcohol day prior test . NUMBER OF PATIENTS : - 200 HCV - 50 match control METHODS : - Patient selection - All patient underwent liver biopsy last 9 month center invite participate study , assume meet inclusion/exclusion criterion . - Patients undergo MBIT data compare result different fibrotic inflammatory score ( i.e . METAVIR ) liver biopsy . One pathologist re-examine biopsy . - Oridion BreathID provide MBIT data 50 healthy control . - Substrate - A test meal consist 75mg PO methacetin + know surface-active ingredient routinely use food drug industry . - Test length - 1 hour - Fasting-8 hour fast . - The patient attach BreathID device via nasal cannula baseline breath measure , test meal ingested device continue measure exhale breath 1 hour . The BreathID device automatically measure change 13C/12C ratio due metabolization methacetin , use spectroscopic principal . The result print automatically end test . STUDY DESIGN : • At first visit physician , patient perform viral load test , liver enzymes test MBIT . A biopsy perform within 9 month test .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>Men woman &gt; 18 Patients HCV RNA+ 105 copy Patients normal liver enzymes two test 3 month apart , &lt; X1.5 upper normal Patients biopsy proven HCV ( 9 month prior test anticipate change liver disease since biopsy ) . Other liver disorder . Active infection . Use drug know induce/suppress P4501A2 Pulmonary diseases Consumption &gt; 20cc alcohol day prior test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>HCV</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Breath test</keyword>
</DOC>